Nextbiotix Receives €7 Million for Development of Bacteria-based IBD Therapy

Nextbiotix Receives €7 Million for Development of Bacteria-based IBD Therapy
Nextbiotix has secured €7 million ($8.2 million) in funding to develop NBX1650, the company’s lead bacterial candidate for the treatment of inflammatory bowel disease (IBD). This first round of funding was led by Auriga Partners, with Sofimac Innovation, Cap Innov’Est, INRA, and Biocodex also contributing. “I am particularly proud to see Nextbiotix coming out of the ground

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *